Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 5/20 | 0.68 |
| ▸ | PRMT3 | O60678 | 5/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.56 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.56 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CBFB | Q13951 | 1/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31514965 | 1.00 | IMPDH2 (0.68) | IMPDH2PRMT3ROCK2ROCK1KDM4E | |
| SCHEMBL30645380 | 1.00 | IMPDH2 (0.68) | IMPDH2PRMT3ROCK2ROCK1KDM4E | |
| SCHEMBL30579695 | 0.85 | IMPDH2 (0.72) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL20262924 | 0.84 | KDM4E (0.66) | IMPDH2PRMT3ROCK2ROCK1KDM4E | |
| SCHEMBL30176801 | 0.84 | KDM4E (0.66) | IMPDH2PRMT3ROCK2ROCK1KDM4E | |
| SCHEMBL8577441 | 0.84 | MEN1 (0.68) | ROCK2ROCK1KDM4EMEN1NPC1 | |
| SCHEMBL19900450 | 0.83 | IMPDH2 (0.66) | IMPDH2PRMT3ROCK2ROCK1 | |
| SCHEMBL31235417 | 0.83 | IMPDH2 (0.66) | IMPDH2PRMT3ROCK2ROCK1 | |
| SCHEMBL19860057 | 0.83 | IMPDH2 (0.66) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL12059122 | 0.83 | IMPDH2 (0.63) | IMPDH2PRMT3ROCK2ROCK1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187681-B2 | Ion channel antagonists/blockers and uses thereof | SHANGHAI EAST HOSPITAL (CN) | 2025-01-07 | — | — | US | disclosed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3811943-B1 | COMPOUND FOR USE IN THE TREATMENT OF OCULAR DISORDERS | AERIE PHARMACEUTICALS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | SHANGHAI EAST HOSPITAL (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | SHANGHAI EAST HOSPITAL (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2021-11-25 | — | — | US | disclosed |
| WO-2021114313-A1 | ION CHANNEL ANTAGONISTS/BLOCKERS AND USES THEREOF | SHANGHAI EAST HOSPITAL (CN) | 2021-06-17 | — | — | WO | disclosed |
| EP-3461484-B9 | DIMESYLATE SALTS OF 4-(3-AMINO-1-(ISOQUINOLIN-6-YLAMINO)-1-OXOPROPAN-2-YL)BENZYL, THEIR COMBINATIONS WITH PROSTAGLANDINS AND THE USE THEREOF IN THE TREATMENT OF OCULAR DISORDERS | AERIE PHARMACEUTICALS INC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3828172-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | Aerie Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-7291602-B2 | 11,12-lactone bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291602-B2 | 11,12-lactone bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| WO-2007115278-A2 | 3,6,11-TRICYCLOLIDE | ENANTA PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070191434-A1 | Inhibitors of bacterial IMPDH | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-16 | — | — | US | disclosed |
| EP-1818334-A1 | ANTI-TRYPANOSOMIASIS AGENT | Japan Science and Technology Agency (JP) | 2007-08-15 | — | — | EP | disclosed |
| EP-1800682-A1 | MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF PARASITIC PROTOZOAN INFECTION | Japan Science and Technology Agency (JP) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007070514-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | CACNA1F, CACNA1S, CACNA1D | IMPDH2 1225/4885PRMT3 4832/4885ROCK2 4748/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | IMPDH2 2094/4885PRMT3 281/4885ROCK2 2066/4885 |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | IMPDH2 236/4885PRMT3 1452/4885ROCK2 3/4885 |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | IMPDH2 236/4885PRMT3 1452/4885ROCK2 3/4885 |
| US-12187681-B2 | Ion channel antagonists/blockers and uses thereof | CACNA1F, CACNA1S, CACNA1D | IMPDH2 1225/4885PRMT3 4832/4885ROCK2 4748/4885 |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | IMPDH2 2129/4885PRMT3 207/4885ROCK2 2090/4885 |
| US-20070191434-A1 | Inhibitors of bacterial IMPDH | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885PRMT3 2140/4885ROCK2 2103/4885 |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | VDR, ESRRB, NR5A1 | IMPDH2 2220/4885PRMT3 3915/4885ROCK2 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.